Pfizer's RSV vaccine shows high efficacy in infants and sets up competition in the vaccine market.
TL;DR Summary
Pfizer's positive late-stage study results for its RSV vaccine have set up a potential $10 billion-plus market showdown with competitors GSK and Moderna. An FDA decision on Pfizer's shot is expected in May, along with a ruling on GSK's vaccine. Moderna's product, still in trials, could compete late this year or early next.
- Pfizer RSV data set up $10B showdown with GSK and Moderna for the next big vaccine market Endpoints News
- Late-stage RSV vaccine trials show 'exciting promise,' some scientists say CNN
- Long-term protection and high efficacy of bivalent BA.1 booster confirmed in older adults News-Medical.Net
- Final data shows Pfizer RSV vaccine 82 percent effective in infants when given to pregnant mothers The Hill
- Pfizer RSV vaccine 82% effective vs severe infection in infants, final data shows Reuters
Reading Insights
Total Reads
0
Unique Readers
2
Time Saved
7 min
vs 7 min read
Condensed
96%
1,400 → 53 words
Want the full story? Read the original article
Read on Endpoints News